Gleevec

(Imatinib Mesylate)

The active ingredient in Gleevec is imatinib. Imatinib is a tyrosine kinase inhibitor that works by blocking specific enzymes involved in cancer cell growth and survival. These include BCR-ABL tyrosine kinase in chronic myeloid leukemia, KIT mutations in gastrointestinal stromal tumors, and PDGFR rearrangements in certain myeloproliferative disorders. By inhibiting these abnormal signals, Gleevec slows or stops the growth of cancer cells and helps control disease progression.

Follow all directions given to you by your doctor and read all documents provided, including the full Prescribing Information, FDA-Approved Product Labeling, Instructions for Use, and Medication Guide before using Gleevec. However, the following is a synopsis of the general guidelines for the use of Gleevec:

Gleevec is taken by mouth as a tablet.

It should be taken with a meal and a large glass of water to reduce stomach irritation.

Tablets may be swallowed whole or dissolved in water or apple juice if swallowing is difficult.

Take Gleevec at the same time each day.

Do not stop taking Gleevec without consulting your healthcare provider.

Some mild or common side effects of Gleevec seen in clinical trials include:

Nausea or vomiting.

Diarrhea.

Muscle cramps.

Joint pain.

Skin rash.

Fluid retention (edema), including swelling around the eyes or ankles.

Weight gain, related to fluid retention.

Loss of appetite.

Some individuals may experience serious side effects while using Gleevec. These side effects may require immediate medical attention. If you experience any of the following, contact your healthcare provider or seek emergency medical help:

Severe fluid retention or heart failure symptoms, such as shortness of breath or rapid weight gain.

Low blood cell counts, including anemia, neutropenia, or thrombocytopenia.

Liver toxicity, including jaundice or abnormal liver function tests.

Severe skin reactions.

Tumor lysis syndrome.

Severe bleeding.

These are not all of the possible side effects of Gleevec. You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment. Read all patient information, medication guides, or drug information sheets that come with this medication. You can also report adverse effects to the Food and Drug Administration at www.fda.gov/medwatch or 1-800-FDA-1088.

Before starting Gleevec, it is crucial to discuss any existing health conditions with your healthcare provider. You should be sure that your healthcare provider is aware of all your medical conditions, including:

Heart disease or heart failure.

Liver disease or abnormal liver function.

Kidney problems.

Low blood cell counts or bone marrow disorders.

A history of fluid retention.

Pregnancy or plans to become pregnant.

Breastfeeding or plans to breastfeed.

Gleevec is contraindicated in patients with known hypersensitivity to imatinib or any component of the formulation.

Gleevec begins working shortly after treatment starts by targeting abnormal cancer cell signaling. Response time varies depending on the condition being treated. Some patients with CML may see hematologic or cytogenetic response within weeks to months. Your healthcare provider will monitor your response through blood tests and other assessments.

When Gleevec is taken with other prescription drugs, over-the-counter medications, vitamins, and supplements, it may change how they work or increase the frequency or severity of side effects. Make sure that you tell your healthcare professional about anything that you are taking to avoid any negative drug interactions, including:

Warfarin may have altered anticoagulant effects when used with Gleevec.

Strong CYP3A4 inhibitors, including grapefruit juice which may increase imatinib levels and side effects.

CYP3A4 inducers, such as St. John’s wort which may reduce imatinib effectiveness.

It is available in 100mg or 400mg tablets.

It should be stored at room temperature, away from the reach of children or pets.

Gleevec is manufactured by Novartis.

Yes, it is available from many manufacturers of generic drugs.

Do not stop taking Gleevec without medical advice. Stopping treatment may cause disease progression.

Gleevec may cause harm to an unborn baby. Talk to your doctor if you are pregnant or planning to become pregnant. Effective contraception is recommended during treatment.

Imatinib passes into breast milk. Breastfeeding is not recommended during treatment and for a period after the last dose. Your healthcare provider can help you decide the safest option.